Jonathan Leslie Tobin
Directeur/Membre du Conseil chez Artios Pharma Ltd.
Provenance du réseau au premier degré de Jonathan Leslie Tobin
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
University of Oxford
258
| College/University | Other Consumer Services | 258 |
Imperial College London
152
| College/University | Other Consumer Services | 152 |
University College London
86
| College/University | Other Consumer Services | 86 |
Brandon Capital Partners Pty Ltd.
 Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.
31
| Private Company | Investment Managers | 31 |
| Public Company | Investment Managers | 19 | |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.
19
| Holding Company | Pharmaceuticals: Major | 19 |
Pheon Therapeutics Ltd.
 Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023.
9
| Holding Company | Biotechnology | 9 |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.
8
| Holding Company | Pharmaceuticals: Major | 8 |
NRG Therapeutics Ltd.
 NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
| Public Company | Medical Specialties | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jonathan Leslie Tobin via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree Undergraduate Degree | |
| BICYCLE THERAPEUTICS PLC | Biotechnology | Chairman Director/Board Member Corporate Officer/Principal Director of Finance/CFO | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Investor Private Equity Investor Consultant / Advisor | |
Global Kinetics Pty Ltd.
 Global Kinetics Pty Ltd. Medical SpecialtiesHealth Technology Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia. | Medical Specialties | Chairman Director/Board Member Director/Board Member | |
AusBiotech Ltd.
 AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Myricx Pharma Ltd.
 Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Chief Executive Officer | |
Oxagen Ltd.
 Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
Transcriptogen Ltd.
 Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Founder | |
| CYCLACEL PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Chord Therapeutics SA
 Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Biotechnology | Chairman Director/Board Member Founder | |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Pathios Therapeutics Ltd.
 Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member Founder Founder | |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
Grey Wolf Therapeutics Ltd.
 Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Founder | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Founder Founder | |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Corporate Officer/Principal Graduate Degree | |
Iroko Pharmaceuticals LLC
 Iroko Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Iroko Pharmaceuticals LLC develops and distributes pharmaceutical products. It provides approved US products, marketed global, medical information and product patents. The company was founded in 2007 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Denteric Pty Ltd.
 Denteric Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Kellogg School of Management | College/University | Masters Business Admin Masters Business Admin | |
Zeneca Pharmaceuticals
 Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Cardiora Pty Ltd.
 Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member | |
| The University of Manchester | College/University | Doctorate Degree Doctorate Degree | |
| King's College London | College/University | Doctorate Degree Doctorate Degree | |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor Private Equity Investor | |
OncoRes Medical Pty Ltd.
 OncoRes Medical Pty Ltd. Medical SpecialtiesHealth Technology OncoRes Medical Pty Ltd. develops an imaging medical device which provides micro-scale images of tissue stiffness and elasticity information to surgeons. The company is headquartered in Nedlands, Australia. | Medical Specialties | Chairman Chief Executive Officer | |
Atopix Therapeutics Ltd.
 Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Elastagen Pty Ltd.
 Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Medical Specialties | Director/Board Member Chief Executive Officer | |
Touchstone Innovations Investment Management Ltd.
 Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Private Equity Analyst Private Equity Analyst | |
| University of Adelaide | College/University | Graduate Degree Doctorate Degree | |
QUE Oncology, Inc.
 QUE Oncology, Inc. Pharmaceuticals: MajorHealth Technology QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Stanford University | College/University | Doctorate Degree Masters Business Admin | |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Chairman Director/Board Member | |
ADC Products (UK) Ltd.
 ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Medical/Nursing Services | Director/Board Member Founder | |
SoniVie Ltd.
 SoniVie Ltd. Medical SpecialtiesHealth Technology SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel. | Medical Specialties | Director/Board Member Director/Board Member | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Founder Director/Board Member | |
| POXEL | Pharmaceuticals: Major | Chairman Director/Board Member | |
| The University of Nottingham | College/University | Doctorate Degree Undergraduate Degree | |
| EBR SYSTEMS, INC. | Medical Specialties | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 18 |
| Royaume-Uni | 15 |
| Australie | 9 |
| Suisse | 4 |
| France | 3 |
Sectorielle
| Health Technology | 32 |
| Consumer Services | 9 |
| Finance | 6 |
| Commercial Services | 5 |
| Miscellaneous | 2 |
Opérationnelle
| Director/Board Member | 460 |
| Corporate Officer/Principal | 143 |
| Chairman | 83 |
| Independent Dir/Board Member | 69 |
| Chief Executive Officer | 64 |
Relations les plus connectées
| Insiders | |
|---|---|
| David C. U'Prichard | 49 |
| Raphaël Wisniewski | 45 |
| Pierre Legault | 45 |
| Barbara Dalton | 35 |
| Regina Hodits | 34 |
| Chen-Ming Yu | 33 |
| Julie Cherrington | 32 |
| René Kuijten | 30 |
| Sten Verland | 28 |
| J. Read | 27 |
| Claudio Nessi | 25 |
| Chris Nave | 24 |
| John Banham | 23 |
| Michael Gladstone | 23 |
| Michael Carter | 22 |
- Bourse
- Insiders
- Jonathan Leslie Tobin
- Connexions Sociétés
